- OXB received the ‘Most Innovative CDMO (Cell & Gene Therapy)’ award at the 2026 CDMO Leadership Awards in New York City.
- The recognition highlights the company’s technology platforms and continued focus on scalable manufacturing for cell and gene therapies.
OXB has been named ‘Most Innovative CDMO (Cell & Gene Therapy)’ at the 2026 CDMO Leadership Awards, held in New York City. The recognition is part of the Jury Awards, which highlight innovation and impact across the contract manufacturing and CDMO sector.
The award reflects OXB’s focus on advancing technologies and platforms in viral vector development and manufacturing. The company stated that its approach is aimed at enabling faster, more scalable, and cost-effective manufacturing solutions for cell and gene therapy developers.
The CDMO Leadership Awards recognize organizations across the industry based on defined criteria, with Jury Awards specifically acknowledging achievements in innovation and leadership. OXB’s recognition places it among companies demonstrating advancements in cell and gene therapy manufacturing capabilities.
“We are proud to receive this recognition for innovation at this year’s CDMO Leadership Awards. It reflects the strength of our technologies and platforms across viral vectors and our continued focus on enabling faster, cheaper, more scalable and high-quality manufacturing for our clients.”
Dr. Sebastien Ribault, Chief Business Officer of OXB
This award follows OXB’s prior recognition in 2025, when the company was named a winner in the ‘Cell & Gene Therapy – Global’ category and later recognized as a Champion in the same category at the CDMO Leadership Awards Europe.
